undamentalytics Newsletter
Sign in

Krystal Biotech, Inc. cash flow statement

In fiscal 2025, Krystal Biotech, Inc.'s operations generated $201m of cash; it spent $12.0m on capital projects, leaving free cash flow of $189m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash from operations−48−101−89123201324
Depreciation and amortisation345666
Stock-based pay153340495555
Capital spending68531241214
Free cash flow−116−154−101119189310
Free cash flow after stock pay−132−187−14170134255
Shares issued3562916000—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ARQT vs KRYSCRMD vs KRYSARDX vs KRYSADMA vs KRYS

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Krystal Biotech, Inc.'s SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Krystal Biotech, Inc.